Pharmacy
Health care outlook 2024: Micah Cost, CEO, PQA
In the second of a two-part series, leaders of industry associations present their expectations for pharmacy operators for this year. Former Defense Secretary Donald Rumsfeld once observed that “there are known knowns. There are things we know we know. We also know there are known unknowns.
Health care outlook 2024: Ronald Piervincenzi, CEO, U.S. Pharmacopeia
In the second of a two-part series, leaders of industry associations present their expectations for pharmacy operators for this year. The past year was significant for the pharmaceutical industry, as we witnessed major milestones and celebrated advancements in innovation.
NACDS unveils new spot on PBM reform
ARLINGTON, Va. – A new television ad from NACDS urges Congress to enact bipartisan pharmacy benefit manager (PBM) reforms that it has advanced in this legislative session.
Health care outlook 2024: Sheila Arquette, president and CEO, NASP
In the first of a two-part series, leaders of industry associations present their expectations for pharmacy operators for this year. The views of other organizations will appear in the next issue of Chain Drug Review. Specialty pharmacy continues to be dynamic, demanding and disruptive.
Health care outlook 2024: Sandra Hanna, CEO, Neighbourhood Pharmacies
In the first of a two-part series, leaders of industry associations present their expectations for pharmacy operators for this year. The views of other organizations will appear in the next issue of Chain Drug Review. 2023 was a momentous year for community pharmacy in Canada.
Health care outlook 2024: B. Douglas Hoey CEO, NCPA
In the first of a two-part series, leaders of industry associations present their expectations for pharmacy operators for this year. The views of other organizations will appear in the next issue of Chain Drug Review. The date January 1 can have varying meanings for people.
Health care outlook 2024: Lee Ann Stember, president and CEO, NCPDP
In the first of a two-part series, leaders of industry associations present their expectations for pharmacy operators for this year.
Health care outlook 2024: Peter Matz, director of Food, Pharmacy and Health Policy at FMI – The Food Industry Association
In the first of a two-part series, leaders of industry associations present their expectations for pharmacy operators for this year. The views of other organizations will appear in the next issue of Chain Drug Review.
Health care outlook 2024: Michael Hogue, CEO, APhA
In the first of a two-part series, leaders of industry associations present their expectations for pharmacy operators for this year. The views of other organizations will appear in the next issue of Chain Drug Review.
Health care outlook 2024: Susan Cantrell, CEO, AMCP
In the first of a two-part series, leaders of industry associations present their expectations for pharmacy operators for this year.
HDA issues statement on FDA approval of Florida’s Rx drug importation plan
Healthcare Distribution Alliance (HDA) president and CEO Chip Davis released the following statement regarding the Food and Drug Administration’s (FDA) decision to authorize the Florida Agency for Health Care Administration’s drug importation program under section 804 of the Federal Food, Drug, and
CVS Health announces leadership appointments
CVS Health announced several leadership updates, effective immediately: • Senior vice president of Corporate Finance and interim CFO, Tom Cowhey, has been formally appointed the company’s next CFO.
CVS partially dropping Humira in favor of cheaper biosimilars
CVS Caremark, a CVS Health company, announced this week the continuation of its efforts to expand adoption of biosimilars. Effective April 1, 2024, Humira will be removed from our major national commercial template formularies and Humira biosimilars will be covered.
Dr. Reddy’s announces the acquisition of MenoLabs
PRINCETON, N.J. – Dr. Reddy’s Laboratories announced that it has acquired MenoLabs business, a leading women’s health and dietary supplement branded portfolio from Amyris, Inc. (“Amyris”) in Amyris’ Chapter 11 sales process. Dr.
Justin Heiser takes the helm at Thrifty White Pharmacy
Justin Heiser has officially taken over as the new president and CEO at Thrifty White Pharmacy. Heiser’s appointment was first announced last May, following the news that Robert (Bob) Narveson president and CEO of Thrifty White Pharmacy for almost 33 years, was stepping down from his role.